行情

BLCM

BLCM

Bellicum制药
NASDAQ

实时行情|Nasdaq Last Sale

1.880
-0.260
-12.15%
盘后: 1.940 +0.06 +3.19% 19:30 01/24 EST
开盘
2.250
昨收
2.140
最高
2.250
最低
1.630
成交量
311.67万
成交额
--
52周最高
4.140
52周最低
0.7211
市值
9,385.85万
市盈率(TTM)
-0.7690
分时
5日
1月
3月
1年
5年

分析师评级

4位分析师的综合评级

强力推荐

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

BLCM 新闻

  • WeWork与软银投资的Gympass签署共享办公空间协议
  • 新浪美股.3小时前
  • NBA神话人物陨落,球星科比坠机身亡
  • 第一财经.4小时前
  • 投资人科比:创办基金公司 投资阿里
  • 新浪科技综合.4小时前
  • 突发!NBA球星科比遭遇直升机意外丧生
  • 新浪财经综合.4小时前

更多

所属板块

生物技术和医学研究
-2.64%
制药与医学研究
-2.00%

热门股票

名称
价格
涨跌幅

BLCM 简况

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.
展开

Webull提供Bellicum Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。